Tysabri - New Efficacy Report and Need for Vigilance
Sustained improvement revealed by post-hoc analysis In addition to updates on the two European patients who developed PML, Biogen and Elan announced that “Tysabri demonstrates sustained improvement in functional outcomes in multiple sclerosis patient according to new post-hoc analysis.” These findings were derived from a... Read more









